1-3 of 3
Emil Freireich, MD
Close
Sort by
Journal Articles

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Aziz Nazha, Carlos E. Bueso-Ramos, MD, PhD, Stefan Faderl, MD, Elihu H. Estey, MD, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, MD, Emil Freireich, MD, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2012) 120 (21): 2616.
https://doi.org/10.1182/blood.V120.21.2616.2616
Published: 2012
Journal Articles

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Dushyant Verma, MD, FACP, Stefan Faderl, MD, Susan O’Brien, MD, Sherry Pierce, Jorge Cortes, MD, Khanh Vu, MD, Emil Freireich, MD, Michael J. Keating, MBBS, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2008) 112 (11): 951.
https://doi.org/10.1182/blood.V112.11.951.951
Published: 2008
Journal Articles

Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy

Gloria Mattiuzzi, MD, Edythe Greenberg, RN, Sherry Pierce, RN, Jorge Cortes, MD, Emil Freireich, MD, Susan O’Brien, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2008) 112 (11): 3988.
https://doi.org/10.1182/blood.V112.11.3988.3988
Published: 2008